BioSpace News Archive

18 BCBS companies to provide $55 million to help create a Civica subsidiary with the goal of bringing lower-cost, generic medications to individuals and families [23-January-2020] CHICAGO and SALT LAKE CITY , Jan. 23, 2020 /PRNewswire/ -- The Blue Cross Blue Shield Association (BCBSA), 18 independent and locally-operated Blue Cross and Blue Shiel

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical results of TNX-801 in a poster at the 2020 ASM Biothreats Conference

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), announced today that it intends to focus on the final development and commercialization of TRUFORMA™, its inaugural point-of-care diagnostic biosensor platform, and the first five assays for the detection of adrenal and thyroid disorders in cats and dogs.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported encouraging interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has entered into a $5,000,000 financing agreement with the Tangiers Global, LLC (“Tangiers”) investment fund

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone, M.D., M.S.C.E., to its board of directors.

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.

Eli Lilly Canada is pleased to announce the approval and availability of a new rescue treatment for severe hypoglycemia, demonstrating Lilly’s commitment to simplifying diabetes management through medicines and patient solutions.

SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning today at 9:30 a.m., EST under the ticker symbol “SWKH.”